Release date: 2010-07-08
The first 10 years of the 21st century is the rapid development of life science and technology for 10 years. A large number of molecular diagnostic products represented by biochips are maturing and are becoming an important tool for human health with their great advantages and application potential.
In the "Institute of Chinese Molecular Diagnostics Technology Conference" held by the Chinese Academy of Engineering, the Chinese Academy of Engineering, the Chinese Academy of Engineering, and the Chinese Medical Association Inspection Branch, the Chinese Medical Association, the Chinese Medical Association, and the Chinese Medical Association. The wonderful academic report made by more than 40 well-known experts, such as Cheng Jing, director of the research center, has launched a beautiful picture of the development of biochip technology in China.
The rapid development of technology "The rapid development of China's biochip technology is dazzling, and the advent of a series of biochips has opened up broad application prospects for disease warning and intervention, personalized diagnosis and prognosis." Professor Cheng Jing first used "difficulty" An idiom vividly describes the speed of development of biochip technology in China.
In the report entitled "Biochip Diagnostic Technology", Cheng Jing said that with the successful completion of the Human Genome Project, more and more genomic and proteomic information has been used for clinical diagnosis, and various information analysis tasks have been undertaken. Biochip technology continues to emerge. In terms of sample preparation, China can now quickly and efficiently separate various molecules and cells in body fluids through various active functional devices on the chip to prepare for the next biochemical reaction. Gene amplification reactions on biochips have also been achieved. In terms of microarray chips, there are various high-density microarray chips such as single nucleotide polymorphism (SNP) and mutation analysis chips and comparative genomic hybridization chips, which are used to discover disease-related biomarkers. The chip lab that integrates various functions is also about to enter the industrialization stage.
In line with clinical effectiveness in recent years, the State Food and Drug Administration (SFDA) has successively approved the genetic deafness gene detection chip, the mycobacterial species identification gene chip and the tuberculosis drug resistance gene detection chip for clinical testing, which marks Molecular diagnostic technology is becoming an important force in clinical laboratory medicine in China.
According to Professor Dai Pu of the Department of Otolaryngology Head and Neck Surgery of the General Hospital of the People's Liberation Army, on the basis of obtaining the type and frequency information of deafness gene mutations in large-scale deaf populations in the country, in order to develop the deafness gene diagnosis system and platform, Boao Biosystems and the PLA General Hospital The 9 most common deafness gene mutation sites were selected in a targeted manner, and the deafness gene chip technology and products based on the allele-specific PCR universal chip (ASPUA) platform were successfully developed. This is currently the most effective testing and screening tool for the Chinese deaf community. Through large-scale promotion of these disease-causing genetic screening and prenatal diagnostic techniques, genetic counseling and intervention can systematically reduce the birth defects and drug-induced deafness in China, and contribute to improving the quality of the birth population in China.
Zhou Hongwei, an academician of the Chinese Academy of Engineering and the chief professor of pharmacology at the National Key Discipline of Central South University, said that the development speed of gene chips has greatly exceeded people's expectations. Individualized drugs will use chip technology to achieve a leap from candidate genes to genome-wide research. Central South University has promoted pharmacogenomics and pharmacogenetics knowledge to clinical practice in various regions of China, providing strong support for safe medication and individualized medication.
Focus on major disease prevention and control Faced with more and more molecular diagnostic products used in clinical laboratory practice, Professor Cong Yulong, president of China Laboratory Physician Branch, said that after continuous clinical practice and experience, especially evidence-based medicine jointly developed with the clinic At work, molecular diagnostic techniques will play an important role in the early detection of some difficult diseases and the health promotion of the people.
Zeng Yixin, a member of the Chinese Academy of Sciences and dean of the Cancer Hospital of Sun Yat-sen University, emphasized that tumors are a multi-system disease involving multiple genes and multiple signaling pathways. Early diagnosis of tumors and early warning of high-risk groups can improve the cure rate and reduce the tumor rate. Mortality is of great importance and molecular diagnostic technology products will play an important role.
(Source: China Medical News)
SUNSON`s Baking Business Division focuses on solutions for flour and flour product processing industries. The major products include complex Baking Enzymes, hemicellulase, lipase, mannanase, glucose oxidase, lipase, fungal amylase, bacterial antistaling α-amylase, xylanase, β-glucanase, phospholipase for bread, sweet rolls and other baked products. The proven effects are better dough handling properties, improved oven spring, crumb structure, crust color freshness, shelf life, and other product quality parameters.
Baking Enzymes
Flour correction, antistaling enzymes, gluten strengthening enyzmes, dough handling enzymes, volume increase enzymes, texture improvement enzymes
Sunson Industry Group Co., Ltd , https://www.sunsonchinaenzymes.com